[go: up one dir, main page]

WO2004034062A3 - Use of cap-1 for the therapy of asthma - Google Patents

Use of cap-1 for the therapy of asthma Download PDF

Info

Publication number
WO2004034062A3
WO2004034062A3 PCT/GB2003/004341 GB0304341W WO2004034062A3 WO 2004034062 A3 WO2004034062 A3 WO 2004034062A3 GB 0304341 W GB0304341 W GB 0304341W WO 2004034062 A3 WO2004034062 A3 WO 2004034062A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
cap
therapy
polypeptide
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/004341
Other languages
French (fr)
Other versions
WO2004034062A2 (en
Inventor
Kevin Bruce Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Peter Reinemer
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Oxford Glycosciences UK Ltd
Original Assignee
Bayer Healthcare AG
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG, Oxford Glycosciences UK Ltd filed Critical Bayer Healthcare AG
Priority to AU2003269257A priority Critical patent/AU2003269257A1/en
Publication of WO2004034062A2 publication Critical patent/WO2004034062A2/en
Publication of WO2004034062A3 publication Critical patent/WO2004034062A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for the treatment of inflammatory diseases including respiratory diseases, such as asthma and asthma related conditions, comprising regulation of the polypeptide (Adenylyl Cyclase-Associated Protein 1/CAP-1), agents which modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of CAP-1 in the diagnosis of inflammatory diseases including respiratory diseases such as asthma and asthma related conditions.
PCT/GB2003/004341 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma Ceased WO2004034062A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003269257A AU2003269257A1 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223272.6 2002-10-08
GB0223272A GB0223272D0 (en) 2002-10-08 2002-10-08 A protein involved in therapy

Publications (2)

Publication Number Publication Date
WO2004034062A2 WO2004034062A2 (en) 2004-04-22
WO2004034062A3 true WO2004034062A3 (en) 2004-06-03

Family

ID=9945455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004341 Ceased WO2004034062A2 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Country Status (3)

Country Link
AU (1) AU2003269257A1 (en)
GB (1) GB0223272D0 (en)
WO (1) WO2004034062A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448990A (en) * 2009-03-30 2012-05-09 普罗塔布有限公司 Adenylyl cyclase-associated protein (CAP1) and its use as immunoregulatory targets
WO2013022262A2 (en) * 2011-08-08 2013-02-14 서울대학교병원 Human resistin receptor, and use thereof
US9933424B2 (en) 2011-08-08 2018-04-03 Seoul National University Hospital Human resistin receptor and use thereof
KR102040974B1 (en) * 2017-01-31 2019-11-06 서울대학교병원 Polypeptides that were derived from adenylyl cyclase-associated protein 1(CAP1) and pharmaceutical composition comprising the same
US12410219B2 (en) 2017-01-31 2025-09-09 Seoul National University Hospital Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
CA3170560A1 (en) * 2020-03-02 2021-09-10 Seoul National University Hospital Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002757A2 (en) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
WO2002048397A2 (en) * 2000-12-11 2002-06-20 Bayer Aktiengesellschaft Regulation of human adenylate cyclase, type vii
WO2002072129A1 (en) * 2001-03-09 2002-09-19 Paula Sundstrom METHODS FOR REGULATING BUD-HYPHA TRANSITIONS AND cAMP LEVELS BY THE ADENYLATE CYCLASE-ASSOCIATED PROTEIN GENE, CAP1
WO2003105884A1 (en) * 2002-06-18 2003-12-24 Oxford Glycosciences (Uk) Ltd Use of shp-1 for the therapy of asthma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002757A2 (en) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
WO2002048397A2 (en) * 2000-12-11 2002-06-20 Bayer Aktiengesellschaft Regulation of human adenylate cyclase, type vii
WO2002072129A1 (en) * 2001-03-09 2002-09-19 Paula Sundstrom METHODS FOR REGULATING BUD-HYPHA TRANSITIONS AND cAMP LEVELS BY THE ADENYLATE CYCLASE-ASSOCIATED PROTEIN GENE, CAP1
WO2003105884A1 (en) * 2002-06-18 2003-12-24 Oxford Glycosciences (Uk) Ltd Use of shp-1 for the therapy of asthma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUBBERSTEY A. ET AL.: "Cyclase-associated proteins : CAPacity for linking signal transduction and actin polymerization.", FASEB J., vol. 16, August 2002 (2002-08-01), pages 487 - 499, XP002273212 *
MANN M. ET AL.: "Analysis of protein phosphorylation using mass spectrometry : deciphering the phosphoproteome", TRENDS BIOTECH., vol. 20, no. 6, June 2002 (2002-06-01), pages 261 - 268, XP004352765 *
PAGE C.P. ET AL.: "Contrasting properties of albuterol stereoisomers.", J. ALLERGY CLIN. IMMUNOL., vol. 104, 1999, pages S31 - S41, XP009027525 *
PAGE M.J. ET AL.: "Proteomics : a major new technology for the drug discovery process.", DRUG DISCOV. TODAY, vol. 4, no. 2, 2 February 1999 (1999-02-02), pages 55 - 62, XP002273211 *

Also Published As

Publication number Publication date
AU2003269257A1 (en) 2004-05-04
WO2004034062A2 (en) 2004-04-22
AU2003269257A8 (en) 2004-05-04
GB0223272D0 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
IL267126B (en) Isolated human rpe cells and use thereof for the treatment of degenerative diseases of the retina
WO2004019884A3 (en) Agents and methods for enhancing bone formation
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
MY172823A (en) Formulation of human antibodies for treating tnf-() associated disorders
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
PT1641483E (en) Fusion proteins
WO2006092668A3 (en) Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
SI1594833T1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2005078124A3 (en) Diagnostic marker for cancer
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
AU6471500A (en) Aqueous nasal formulation
WO2003011327A3 (en) Secretin for the treatment of asthma
SE0102147D0 (en) New methods
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
EP1281763A3 (en) Early growth response-1 (EGR-1) transcription factor
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
WO2002051379A3 (en) Thixotropic nasal spray
TW200719908A (en) Dermatologic use of milk proteins
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP